PGGT1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL446562	0.54	18/20
SCHEMBL444432	0.69	16/20
SCHEMBL454305	0.82	15/20
SCHEMBL454059	0.60	14/20
SCHEMBL455063	0.60	14/20
SCHEMBL452628	0.60	14/20
SCHEMBL461730	0.65	13/20
SCHEMBL455264	0.63	13/20
SCHEMBL453991	0.59	13/20
SCHEMBL454433	0.56	13/20
SCHEMBL460646	0.62	12/20
SCHEMBL453965	0.50	12/20
Cisconazole (SCHEMBL394070)	0.68	11/20
SCHEMBL454748	0.60	11/20
SCHEMBL453392	0.63	10/20
SCHEMBL455458	0.51	10/20
SCHEMBL444433	0.50	10/20
SCHEMBL875627	0.50	10/20
SCHEMBL463380	1.00	9/20
SCHEMBL455290	0.81	8/20

Clinical trials — most relevant to PGGT1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)	PHASE4	UNKNOWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
Study of the Mechanisms of Asthma	PHASE1	COMPLETED
GSNOR Phenotyping/GSNO Challenge in Severe Asthma	EARLY_PHASE1	COMPLETED
Cross-sectional Characterization of Idiopathic Bronchiectasis	nan	COMPLETED
Collaborative Studies on the Genetics of Asthma (CSGA)	nan	COMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Personalised Therapeutics @LUMC	nan	ACTIVE_NOT_RECRUITING
Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)	nan	COMPLETED
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Genetic Epidemiology of Asthma in Costa Rica	nan	COMPLETED
Identification of an Asthma Susceptibility Gene on 3P	nan	COMPLETED
Tolerance in Beekeepers	nan	RECRUITING
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma	nan	RECRUITING
Longitudinal Observational Study of Severe Asthma	nan	COMPLETED
Pediatric Evaluation and Registry for Liver Cholestasis in Canada	nan	RECRUITING
Molecular Mechanism of Asthma	nan	WITHDRAWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
The Role of Epigenetics in Inner City Asthma	nan	COMPLETED
Characterizing a 5P-Linked BHR Susceptibility Locus	nan	COMPLETED
B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma	nan	UNKNOWN
Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PGGT1B binder may also engage these)

Protein	Name	Similarity
Q8BUY9	—	1.000	Q8BUY9 →
P53610	—	1.000	P53610 →
Q5EAD5	—	1.000	Q5EAD5 →
RABGGTB	Geranylgeranyl transferase type-2 subunit bet	0.988	landscape →
P53612	—	0.987	P53612 →
Q8K2I1	—	0.984	Q8K2I1 →
Q5E9B3	—	0.982	Q5E9B3 →
FNTB	Protein farnesyltransferase subunit beta	0.982	landscape →
Q84J75	—	0.982	Q84J75 →
P41992	—	0.982	P41992 →
Q08603	—	0.981	Q08603 →
P49355	—	0.981	P49355 →
Q02293	—	0.981	Q02293 →
Q9LHL5	—	0.980	Q9LHL5 →
O93830	—	0.979	O93830 →
P20133	—	0.975	P20133 →
P46960	—	0.973	P46960 →
Q04903	—	0.972	Q04903 →
B0G172	—	0.970	B0G172 →
P18898	—	0.968	P18898 →
Q55DA3	—	0.967	Q55DA3 →
P22007	—	0.966	P22007 →
O13782	—	0.966	O13782 →
A0A0S2IHL6	—	0.965	A0A0S2IHL6 →
F4IEM5	—	0.964	F4IEM5 →
A0A067FI21	—	0.964	A0A067FI21 →
P0C8Y0	—	0.964	P0C8Y0 →
Q6BE24	—	0.964	Q6BE24 →
O80642	—	0.963	O80642 →
A0A125SXN3	—	0.963	A0A125SXN3 →